TO INITIATE MONITORING, YOU NEED: STARLING MONITOR AND SENSORS

Power On > New Patient > Enter Patient ID/Age/Wt/Ht/Gender > Start Session > Automatically Calibrates

DOES MY PATIENT HAVE A LOW BLOOD PRESSURE/MAP OR PERFUSION PROBLEM (I.E., LOW UOP/HIGH LACTATE)? DO I NEED TO GIVE FLUID?

(only ~50% of hemodynamically unstable patients are fluid responsive!')



Results³: ≥10% ΔSVI patient is likely fluid responsive <10% ΔSVI (including negative numbers) patient is not likely fluid responsive

"Would you like to start immediately from the challenge stage?" means "Can I use the last 3 minutes of SVI data as my baseline?" (i.e, no nursing interventions)

"Baseline shows unstable results" means the last 3 SVI readings have changed more than 10%. Consider repeating baseline.



CALIBRATION VS. BASELINE:

Calibration = signal optimization occurs during initial pt. set-up.

Baseline = initial SVI readings of a dynamic assessment



SENSORS:

- "Box in" the heart
- Red dashes indicate right/ left and upper/lower
- White tabs point to toes
- Can be on front or back in any combination

NEED TO RECALIBRATE:

(Session Controls > Recalibrate)

- If any or all sensors are moved or replaced
- Once a shift

Patient

- Shock States/Low Blood Pressure: Sepsis, Low Vascular Tone, Low Cardiac Output, Hypovolemia, Neurogenic Shock⁴
- Patients treated with Inotropes, Vasopressors or Vasodilators⁴
- Surgical Patients: Perioperative Volume Management, Goal Directed Therapy, Enhanced Recovery After Surgery (ERAS)⁵
- Emergency/Trauma Patients⁶
- Other Critical Care Conditions: Acute Respiratory Distress (ARDS), Sub-Arachnoid Hemorrhage (SAH), Acute Kidney Injury (AKI), and Congestive Heart Failure (CHF)10
- Patients undergoing Continuous Renal Replacement Therapy (CRRT) or patients undergoing hemodialysis¹¹

ONLY ~50% of hemodynamically unstable patients will respond to fluid by increasing cardiac output and perfusion.1

Parameters	Normal Adult Range ¹³	Cardiogenic Shock	Septic Shock	Hypovolemic Shock
BP (MAP)	> 65	+	1	1
Heart Rate (HR)	60-100	1	1	•
Cardiac Index (CI)	2.5-4.0 L/min/m ²	+	early late	early late
Total Peripheral Resistance Index (TPRI)	1970-2390 dynes • sec/cm ⁵ /m ²	1	1	1
Common Stroke Volume Response (ΔSVI) to Dynamic Assessment		ΔSVI <10%	ΔSVI ≥10%	ΔSVI ≥10%

ΔSVI ≥10% Predictive of 15% increase in CO with 500cc¹⁴

Dynamic Assessments Directly Challenge the Heart with Volume to Measure its Response:

Passive Leg Raise (PLR) Maneuver — Translocation of 250-300cc of blood from lower extremities into the heart3 • Fluid Bolus Challenge (FB) — Rapid Infusion of 250cc of fluid over 3-5 minutes3

Parameters	Equation	Normal adult range	
Stroke Volume (SV)	CO/HR x 1000	60 – 100 mL/beat	
Stroke Volume Index (SVI)	SV/BSA	33 – 47 mL/beat/m²	
Δ Stroke Volume Index (ΔSVI)	Change in SV after Dynamic Assessment	≥10% Likely to be Fluid Responsive³ <10% Unlikely to be Fluid Responsive³	
Cardiac Output (CO)	HR x SV/1000	4.0 – 8.0 L/min	
Cardiac Index (CI)	CO/BSA	2.5 – 4.0 L/min/m²	
Mean Arterial Pressure (MAP)	(SBP + (2 x DBP))/3	70 – 105 mmHg	
Total Peripheral Resistance (TPR)	80 x (MAP)/CO	800 – 1200 dynes • sec/cm⁵	
Total Peripheral Resistance Index (TPRI)	80 x (MAP)/CI	1970 - 2390 dynes • sec/cm⁵/m²	

ΔSVI ≥10% Predictive of 15% increase in CO with 500cc¹⁴

$\label{lem:continuous} \textbf{Dynamic Assessments Directly Challenge the Heart with Volume to Measure its Response:}$

Passive Leg Raise (PLR) Maneuver — Translocation of 250-300cc of blood from lower extremities into the heart³ • Fluid Bolus Challenge (FB) — Rapid Infusion of 250cc of fluid over 3-5 minutes³

1. Bentzer P, Griesdale D, Boyd J. Will this hemodynamically unstable patient respond to a bolus of intravenous fluids? JAMA_ 2016;3161(2):1298-1309. 2. Aya HD, Ster IC, Fletcher N, et al. Pharmacodynamic analysis of a fluid challenge. Crit Care Med. 2016;46:880-891. 3. Cecconi M, Parsons AK, Rhodes A. What is a fluid challenge? Curr Opin Crit Care. 2011;1(73);290-295. 4. Marik P, Levitov A, Young A, Andrews L. The use of bioreactance and carotid Doppler to determine volume responsiveness and blood flow redistribution following passive leg raising in hemodynamically unstable patients. Chest. 2013;143:364-370. 5. Waldron N, Miller T, Thacker J, et al. A prospective comparison of a noninvasive cardiac output monitor versus esophageal Doppler monitor for goal directed fluid therapy in colorectal surgery patients. Anesth Analg. 2014;118:966-975. 6. Dunham CM, Chiricella T, Gruber B, et al. Emergency department noninvasive (NICOM) cardiac outputs are associated with trauma activation, patient injury severity and host conditions and mortality. J Trauma Acute Care Surg. 2012;3:479-485. 7. National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Comparison of two fluid management strategies in acute lung injury. New Engl J Med. 2006;254:2564-2575. 8. Mittal M, Radhakrishnan M, Uradham S, et al. A multicenter study of noninvasive cardiac output by bioreach patients. 2015;27:527-530. 9. Grams ME, Estrella M, Coresh J, et al. Fluid balance, diuretic use, and mortality in acute kidney injury. Clin J Am Soc Nephrol. 2011;6:966-973. 10. Maurer HM, Burkeft D, Maybaun S, et al. A multicenter study of noninvasive cardiac output by bioreachance during symptom-limited exercise. J Card Fail. 2009;15:689-699. 11. Kossari N, Hugnagel G, Squara P. Bioreactance: a new tool for cardiac output and thoracic fluid content monitoring during hemodialysis. Hemodial Int. 2009;15:69-699. 11. Kossari N, Hugnagel G, Squara P. Bioreactance: a new tool for cardiac output and thoracic fluid conte

DISCLAIMER: This document and all content in it are for general information purposes only and are not intended to be specific medical advice, medical opinion, diagnosis or treatment as applied to any particular patient's condition or situation. Please do not rely on this document or its content as a substitute for the expertise and professional judgment of a physician, pharmacist, nurse, or other healthcare professional.

Baxter and Starting are trademarks of Baxter International Inc. or its subsidiaries.

USMP/CHE/20-0020 04/20